Immune Response in Lung Cancer (IRLC)

Lithuanian University of Health Sciences

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01955343

IRLC-1109

Details and patient eligibility

About

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

Enrollment: 100 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eastern Cooperative Oncology Group (ECOG) score of 0-1
• Patients with histologically documented non-small cell lung cancer
• Control group - patients without non-small cell lung cancer
• Written (signed) Informed Consent to participate in the study

Exclusion criteria

• Any other malignancies within 5 years
• Any unstable systemic disease (including active infections, significant cardiovascular disease)
• Prior chemotherapy or radiotherapy
• Autoimmune disease
• Nursing or pregnant women

Trial design

100 participants in 2 patient groups

Lung cancer

Description:

Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)

Control

Description:

Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies